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Abstract 
BACKGROUD: Spinal cord injury (SCI) is damage that can cause a temporary or permanent change in spinal 
cord functions. 
AIM: This work evaluates clinical signs, mental signs, and quality of life (QoL) after autologous adipose-derived 
stem cells (ADSCs) transplantation to treat acute spinal cord injury (SCI). 
METHODS: In this study, 47 SCI patients were recruited and divided into two groups: intervention and control. 
ADSCs were isolated and cultured under the cell culture quality control procedure. All patients in both groups 
underwent neurosurgery with or without ADSC transplantation. The recovery regarding neurological muscle, QoL, 
neurogenic bladder, and mental improvement was assessed after transplantation. 
RESULTS: All patients had improved in terms of motor function, bladder function, and daily living. No patients 
reported any side effect. MRI imaging showed significant changes in the lesion length of the spinal canal and the 
thickening of the spinal cord. Mental improvement was highest at six months after transplantation and lowest at 
one month after transplantation. The proportion of patients whose quality of life improved after treatment was 
100%, while 80% of patients were satisfied with treatment outcomes. 
CONCLUSIONS: Thus, our data suggested that ADSCs transplantation was safe and effective for the treatment 
of SCI patients. Neurological muscle and neurogenic bladder were improved significantly after transplantation. 
 
 
 
 
Introduction 
 
Spinal cord injury (SCI) is damage that can 
cause a temporary or permanent change in spinal 
cord functions. SCI causes a variety of severe issues 
such as loss of bowel faculties, sensory and motor 
function impairment, and intractable pain. It can be 
categorized as primary and secondary injuries — both 
share a common mechanism that leads to the death 
of glial and neuronal cells, demyelination, axonal 
degeneration, and consequently manifests as severe 
impairment in neurological functions [1]. SCI can be 
treated by several methods such as surgical 
decompression and fixation, and physical 
rehabilitation; however, these treatment methods still 
have some limitations [2]. 
Stem cell therapy has emerged and been 
applied successfully in the treatment of many 
diseases. It has also shown potential as a treatment 
method for disorders in the refractory nervous system, 
including SCI. In the most recent cell therapy clinical 
trials for SCI, mesenchymal stem cells (MSCs) were 
specifically studied for their therapeutic potential in 
various treatment modalities such as modulation at 
the injury site, cell rescue, promotion of directed 
progenitor precursor cell migration, differentiation and 
re-myelination, angiogenesis, and neovascularization 
[3]. There are a number of MSC types applied in SCI 
treatment in which the stem cells are isolated from 
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bone marrow (bone marrow stem cells – BMSCs), 
umbilical cord blood (umbilical cord blood cells – 
UCBCs), adipose tissues (adipose-derived stem cells 
– ADSCs) and placental MPCs [4]. 
It is also well-known that subcutaneous 
adipose depots are ubiquitous, thereby, providing a 
higher number of MSCs compared to bone marrow 
[5]. Adipose tissue contains multipotent cells that are 
suitable to develop stem cell therapies. It is evident 
that the number of stem and progenitor cells in 
stromal vascular fraction (SVF) from fat tissue can be 
3%, which is 2500-fold higher compared to the 
population isolated from bone marrow [6]. 
Additionally, ADSCs are easily isolated, 
cultured, and widely used in basic and clinical 
research, and the stem cell extraction technique for 
ADSCs (e.g., liposuction aspiration) is less invasive 
compared to bone marrow aspiration. Liposuction 
surgery is safer, less invasive, and cheaper in stem 
cell isolation [7], [8]. Stem cell therapy based on 
ADSCs can take advantage of lipoaspirate, which is 
considered as medical waste, as a good source for 
stem cells. 
The application of ADSCs therapy has been 
explored in various treatments for conditions such as 
myocardial infarction, heart failure, diabetes, and 
obesity [9], [10], [11], [12], [13], [14], [15]. A recent 
systematic review and meta-analysis indicated that 
treatment for SCI using stem cell transplantation is 
efficient and safe, with improved sensory and bladder 
functions [16]. Besides, hADSCs could be converted 
into electrophysiologically active motoneuron-like cells 
(hADSC-MNs). After transplantation, they survived, 
migrated, and integrated into the injured site and this 
led to partial functional recovery in SCI mice. These 
results suggest the use of ADSC for cell replacement 
therapy for spinal cord injury [17]. The safety and 
feasibility of autologous ADSCs in SCI treatment on 
humans have not been fully explored. Thus, this study 
evaluates the safety and feasibility of autologous 
ADSCs transplantation for treating acute SCI, in terms 
of clinical signs, mental signs, and quality of life. 
 
 
Materials and Methods 
 
Participants 
Patients were eligible if they A) were aged 
from 18 to 60 years and B) had an acute complete 
SCI (e.g., ASIA-A, between T1 and T12 of traumatic 
etiology within 2 weeks). They were excluded if they 
A) were under mechanical ventilation; B) had 
diseases other than SCI (e.g., melanoma within 5 
years); C) had an infectious diseases (i.e., HIV); body 
temperature higher than 38°C; D) had a predisposing 
disease (e.g., thrombocytopenia); E) received 
cytotoxic drug treatment; F) were participating in a 
clinical trial within 3 months; G) had current 
psychiatric illness; H) had traumatic brain injury 
related to SCI, or I) did not provide fully informed 
consent. 
Based on the inclusion and exclusion criteria, 
100 participants were screened. Then, the participants 
were randomly allocated into treatment and control 
group with the ratio 2: 1, respectively. Of the patients 
screened, 48 met the inclusion criteria and were 
allocated a group, with 32 in the treated group and 16 
in the control group, which consisted of 18 males and 
2 females aged 18 – 59 years old. One patient in the 
treatment group withdrew from the study for personal 
reasons. Finally, 47 patients were included in the 
analysis, with 31 in the treated group and 16 in the 
control group (Figure 1) (Table 1 and Table 2). 
 
Figure 1: Flow chart of patients from recruitment to the end of 6-
month randomized control trial; There were 100 patients assessed 
for eligibility if they A) were aged from 18 to 60 years and B) had an 
acute complete SCI; They were excluded, if they A) were under 
mechanical ventilation; B) had diseases other than SCI (e.g., 
melanoma within 5 years); C) had an infectious disease (i.e., HIV); 
body temperature higher than 38°C; D) had a predisposing disease 
(e.g., thrombocytopenia); E) received cytotoxic drug treatment; F) 
were participating in a clinical trial within 3 months; G) had current 
psychiatric illness; H) had a traumatic brain injury related to SCI, or 
I) who did not provide fully informed consent; Screening based on 
inclusion and exclusion criteria resulted in 100 participants. Then, 
the participants were randomly allocated into treatment and control 
group with the ratio 2: 1, respectively. Of the patients screened, 48 
met the inclusion criteria and were allocated groups, with 32 in the 
treated group and 16 in the control group, which consisted of 18 
males and 2 females aged 18-59 years old. One patient in the 
treatment group withdrew from the study for personal reasons. 
Finally, 47 patients were included in the analysis, with 31 in the 
treated group and 16 in the control group 
 
The ratio of patients in treatment/control 
group was 2: 1; patients in the treatment group 
received surgical decompression and spinal fix using 
the classic method and then they were transplanted 
with the stem cells, while the other group received 
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only surgical decompression and spinal fix using the 
classic method. The assumption was that the real 
recovery rate was applied to AIS A after 7 days: 3% in 
control candidates (based on the data above) after 
one year for AIS C, and a 23% recovery effect for 
actually-treated candidates. At baseline, there are no 
differences between intervention and control group 
regarding basic characteristics such as mean age, 
proportion of male, and level of injury as well as AIS-A 
(Table 1). 
Table 1: Summary results 
Patients number (n) 
Patients 
Motor 
change 
EMG/SSEP 
change 
MRI 
change 
Bladder 
function 
change 
Improve in 
daily living 
Side 
effect 
Time 
observation 
N = 31 2 3 31 3 31 0 3 months 
N = 31 5 3 31 9 31 0 6 months 
N = 31 5 3 31 11 31 0 12 months 
 
The sample size was based on several 
factors such as important clinical differences and 
setting the sensory/motor score on the AIS scale. In 
addition, clinical experts in the field were asked for 
clinical outcomes that were needed to determine 
significant improvement in both AIS and success rates 
in-patient rehabilitation. In this study, the treatment 
was clinically significant if 20% or more cases 
appeared to improve AIS scores from A to B (Table 
2). 
Table 2: Change in ASIA between treatment and control group 
AIS 
12 months after injection Total 
A B C D E 
Control group A 15 1 0 0 0 16 
Treatment group A 16 10 1 2 0 31 
Total 31 11 1 2 0 47 
AIS: American Spinal Injury Association Impairment Scale. 
 
Adipose-Derived Stem Cells Culture 
Participants in the transplant group underwent 
stomach anesthesia for liposuction. Fat tissues was 
injected with 100 mL 0.9% sodium chloride mixed with 
5 mL 1% lidocaine, 1 ml adrenaline (1mg/mL), and 
then 80 mL fat tissue was aspirated into the syringe. 
The fat syringes were placed immediately into a sterile 
cold container. The collected fat tissues were 
transported from the operation room (Viet Duc 
Hospital) to the isolation facility (Tri Phuoc Company). 
Fat tissues were totally manipulated in sterile 
lamina to isolate ADSCs. The tissues were washed 
briefly in PBS plus antibiotics, digested by DMEM 
containing collagenase type I at 37°C in a water-bath 
shaker for 40 – 60 minutes, followed by centrifugation 
to remove undigested fat tissues. After centrifugation, 
the supernatant was then discarded, the stromal 
vascular fraction (SVF) was resuspended in a stromal 
medium. ADSCs were counted under a microscope, 
identified by surface marker expression of MSCs, and 
tested for sterility. Then, half of the SVF were diluted 
in 8 mL sodium chloride 0.9% and transferred to a 
syringe for the first injection. The cell-storing syringe 
was placed in a sterile cold container and was 
transferred back to Viet Duc Hospital. 
The rest of the cells were seeded in a flask 
and incubated at 37°C with 5% CO2, the medium was 
changed every 48 hours [18]. Those cells were 
passaged when they were 80% confluent. After the 
second passage, ADSCs were divided into 3 parts, 
each corresponding to an injection. Each part was 
mixed with freezing protective agents at 80°C for 24 
hours and stored in liquid nitrogen. Ten days prior to 
transplantation, the cells were quickly thawed at 37°C 
and sub-cultured for 1 – 2 next passage times. On 
transplantation day, the cells were harvested using 
trypsinization, then transferred into a sterile syringe at 
a concentration of 30 x 10
6
 cells/8 mL 0.9% NaCl for 
the 2nd and 3rd injection, and a concentration of 
100 x 10
6
 cells/10 mL 0.9% NaCl for the 4th injection, 
and delivered to the operating hospital. 
 
Cell Quality Control 
Immunophenotyping characterization of the 
cell population was done by flow cytometric analysis. 
The freshly-isolated SVF and ADSCs were 
immunophenotyped before any transplantation. To 
identify the surface markers of MSCs, such as CD73, 
CD105, CD90, CD166, 1 x 10
6
 cells dissolved in 1 mL 
PBS were used. The morphology of the cells was 
observed using a microscope. All materials and media 
in the procedure adhered to WHO-GMP, ISO 9001-
2008, and ISO 15189 standards to ensure sterility. 
 
 First Transplantation 
 In the same day, the participants in each 
group underwent surgery in which the spinal cord 
received fix and decompression, liposuction, and first 
transplantation.  
We adapted the procedure of transplantation 
by Féron et al., (2005) using adipose tissue instead of 
olfactory ensheathing cells [19]. All patients received 
general endotracheal anesthesia before starting 
transplantation. The incision line was infiltrated with a 
mixture of adrenaline: lidocaine with rate 1: 100000. 
Before performing the surgery, an x-ray was done to 
locate the lesion site and stem cell infusion site. Five 
main surgical steps were performed to deliver the 
stem cells to the injury site: 1) Midline incision at the 
vertebral column rostral and caudal to the site of the 
injury; 2) Dura bared at the site of injury through 
rostral and caudal multiple level laminectomies. 
Extreme caution should be taken so facet joints would 
not interfere; 3) Midline durotomy away from the injury 
site. To complete the opening of the durotomy, normal 
dura and sharp dissection was done after removing 
adhesions through the injury; 4) Dorsal adhesiolysis 
under the magnification of an operating microscope 
through sharp and blunt dissections in the injury site. 
This was done to restore the structure of the cord to 
as normal as possible; 5) Two mL SVF solutions were 
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delivered to the subarachnoid space of the injury at 
above, center, and below of injury site. The remaining 
cell solution was injected into subarachnoid space 
before closing duration  [16], [17], [18], [19]. 
 
Second and third ADSCs Transplantation 
Second and third ADSCs transplantation took 
place on day 30, and day 45 respectively. At which 
point, 30 x 10
6
 cells/8 mL 0.9% NaCl was delivered 
into the lumbar spine. 
 
Fourth ADSCs Transplantation 
Fourth ADSCs transplantation took place on 
day 75, when 100 x 10
6
 cells/8 mL 0.9% NaCl was 
intravenously injected into the lumbar spine.  
 
Recovery measurements 
The patients were observed and assessed for 
neurological muscle recovery at 3 months and 6 
months after the first injection through (1) 
somatosensory evoked potentials (SSEPs); (2) cord 
recovery at injury site using MRI; and (3) neurogenic 
bladder improvement using Exploration Urinary 
Kinetics (EUK). Mental improvements were also 
evaluated using (1) the Short Form 36 items (SF-36) 
index; (2) Oswestry; and (3) Barthel Index of Activities 
of Daily Living (BIADL). The quality of life (QoL) was 
evaluated by short-form 36 items (SF-36), and patient 
satisfaction with treatment results was measured. 
 
Statistical analysis 
SPSS (SPSS Inc., Chicago, III, v.20 for 
Windows) was used data analysis, and statistical 
analysis was done by t-Test. P-value of < 0.05 was 
employed to identify statistical significance unless 
otherwise indicated.  
 
Figure 2: CD73 marker – MSC culture in Phase 2 with positive 
percent (97.5%). Adipose-derived stem cell cultures predominantly 
contain MSCs identified by immunostaining for CD73. The 
percentages of CD 73
+
 cell ranged 97.5%, which contained the 
majority of adipose-derived stem cells 
 
 
Results 
 
Adipose-Derived Stem Cell Culture 
The cultured cell presented characteristics of 
ADSC/MSC, which followed the criteria of the 
IFATS/ISCT [20]. The percentages of MSCs ranged 
from 86–99% (Figure 2). No cell was positive for 
CD14 (a marker for hematopoietic stem cells) (Figure 
3). For fresh SVF, the percentages of CD73, CD90, 
CD105, and CD166-positive ranged from 61 to 68%; 
CD14-positive cells were at 8% of the total cell 
population. 
 
Figure 3: CD14 marker – MSC culture in Phase 2 with positive 
percent (0%). The adipose-derived stem cell cultures were checked 
with CD14 marker, a marker for hematopoietic stem cells. The 
result showed no cell was positive for CD14 
 
Electrophysiological parameters 
Changes in motor function were recorded 
based on complete paraplegia or quadriplegia. In the 
study, three out of five patients recovered motor 
functions (Table 1); they could stand and walk on their 
own legs without support or with a little assistance. 
Three patients had SSEP changes with the cortical 
response on tibia nerves and positive P37. Changes 
in electromyography (EMG) were recorded in three 
patients showing some motor units on the muscle 
electromechanical table (Figure 4). 
 
Figure 4: Changes in Electromyography (EMG) in the treatment 
versus the control group. The electromyography (EMG) was 
recorded in the treated group and compared to the untreated group. 
The results showed some motor units on the muscle 
electromechanical table 
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Radiology 
Changes in the lesion length of the spinal 
canal, thickening of the spinal cord, and MCC and 
MSCC were statistically significant (p < 0.05) at time 
points of 3 months and 6 months compared to before 
treatment.  
Table 3: MRI results of 31 patients, 3 months after the first 
injection 
 L (mm) R (mm) MCC (%) MSCC (%) 
Before treatment 
(n = 31) 
60.97 ± 3.934 6.18 ± 0.486 32.73 ± 2.950 36.95 ± 3.193 
3 months after 
first treatment 
(n=31) 
48.548 ± 3.998 7.76 ± 0.320 20.38 ± 2.165 19. 23 ± 1.934 
P-value P = 0.0179 P = 0.0122 P = 0.0013 P < 0.01 
L: lesion length, R: thickening of the cord, MCC: maximum spinal canal compromise, 
MSCC: maximum spinal cord compression, (p values were determined by t-test). 
 
These changes were recorded using MRI 
(Table 3) (Figure 5). 
 
Figure 5: Comparison of a lesion in MRI; A) Before treatment; B) 3 
months after the first treatment; and C) 6 months after the first 
treatment; The MRI image of the lesion region was taken before the 
treatment A); 3 months after the first treatment B); and 6 months 
after the first treatment C); B) and C) present the recovery of the 
injured spinal cord 
 
Neurogenic bladder measurement 
There were changes in neurogenic bladder 
recorded based on significant changes in the 
involuntary bladder contractions, maximum bladder 
pressure (Pdetmax), and maximum bladder volume 
(VH2Omax) (Table 4).  
Table 4: MRI results of 31 patients, 6 months after the first 
injection 
 L (mm) R (mm) MCC (%) MSCC (%) 
Before treatment 
(n = 31) 
51.34 ± 5.052 5.75 ± 0.559 27.135 ± 3.968 29.43 ± 3.674 
6 months after first 
treatment (n = 31) 
36.94 ± 4.083 8.59 ± 0.448 13.59 ± 1.67 11.14 ± 1.599 
P-value P = 0.0343 P = 0.0004 P = 0.0037 P = 0.0001 
L: lesion length; R: thickening of the cord; MCC: maximum spinal canal compromise; 
MSCC: maximum spinal cord compression; p values were determined by t-test. 
 
However, this result does not reflect the 
effectiveness of treatment because it depends on the 
care of the bladder and rehabilitation after treatment 
(Table 5). 
Table 5: Result for changes in involuntary bladder contractions 
Months after the first 
treatment 
n Mean ± Stand P 
3 18 2.5 ± 0.246 
P < 0.01 
6 10 0.4 ± 0.221 
p values were determined by t-test. 
 
Mental improvement 
SF-36 results showed that the general QoL of 
the patients improved from poor to good, while the 
back-pain rate, which affects patients’ daily activities, 
measured through the Oswestry questionnaire, 
changed from serious to mild. Barthel ADL increased 
to 3 points at 6 months after the first treatment (Table 
6). No side effects were reported during 6 months 
after treatment. 
 
Quality of life 
All patients rated their quality of life improved 
after treatment. Moreover, 80% of patients reported 
that they were satisfied and happy with the results of 
the treatment. 
Table 6: Mental improvement of patients in different time 
points 
Index 
Before 
treatment 
(n = 31) 
1 month after 
first treatment 
(n = 31) 
3 months after 
first treatment 
(n = 31) 
6 months after 
first treatment 
(n = 31) 
SF-36 score 23.50 ± 7.89 31.60 ± 11.18 41.25 ± 13.35 53.16 ± 14.47 
General quality of 
life 
Bad Bad Average Excellent 
Oswestry 79.48 ± 7.33 73.38 ± 8.07 65.41 ± 7.55 58.22 ± 7.66 
Back pain level Serious Serious Mild Mild 
Barthel ADL 3.35 ± 1.35 4.41 ± 1.78 5.51 ± 2.06 6.48 ± 2.14 
 P-value P < 0.05 P > 0.05 
p values were determined by t-test. 
 
 
Discussion 
 
SCI patients have shown significant 
improvement after autologous ADSCs therapy. Of the 
patients, 48.1% exhibited improved functions based 
on the AIS scale (A-B) after 6 months. Further follow-
up with patients for the next 9 months showed 7.4% of 
patients at the B-C level. Clinical evaluation according 
to the AIS scale reflected the extent of anatomical 
lesions. In MRI imaging, hematoma and compression 
support clinicians regarding prognosis, recovery, and 
post-transplant evaluation through MCCs and 
MSCCs. We found that there were statistically 
significant differences between the study groups. 
Although MRI has limited discrepancies between 
white matter and gray matter, the use of MCCs and 
MSCCs combination with the AIS scale is a good way 
to predict marrow recovery. 
Further, the result of our study was congruent 
with other published data. Cases in point, a study by 
Park et al., (2005) reported that the application of 
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MSCs in 18-month spine trauma patients resulted in 
improvement of 6/20 (20%) patients with A – B 
changes [21]. Another US multi-center study of 1816 
patients with 50 randomly selected stem cell 
transplant recipients scored 3/13 patients who 
improved on the AIS (AC) scale [16]. A study by Yoon 
et al., (2007) demonstrated that after one year of 
follow-up, 29.5% of patients who received stem cell 
transplant had neurological recovery (A – B) [22]. 
Ramesh Kumar et al., (2011), in a study of 24 
patients, reported a 30% increase in the MCC and 
MSCC scores to assess changes in the structure of 
the spinal cord [17]. This was similar to our finding in 
this study, in which the index was 33.5%. 
We used both direct and indirect injection at 
different times, and cells were cultured to obtain 
enough numbers per time point. The clinical efficacy 
of the transplant was evaluated. The combination of 
stem cells transplanted into the lumbar at L2 and the 
intravenous infusion was also a highlight in this study. 
Elevated efficacy through cerebrovascular drainage 
and acute myeloid lesions provide anti-inflammatory, 
directed, and attractive cytokines by the homing 
mechanism to the lesion site. In this study, we have 
not applied grafting techniques and tissue fixators. 
There are some limitations to this study. The 
sample size was limited and we only conducted the 
study in one hospital. The follow-up duration was 6 
months. Additionally, preoperative and postoperative 
imaging methods such as MEP and MRI were 
insufficient. Regarding cell quality, the survival rate 
and the number of cells differentiated were not 
investigated. 
The study is still on-going in several centers 
that have a follow-up period of five years. We will 
conduct a further subgroup study in chronic patients 
or in patients’ ages possibly with many different cell 
sources such as bone marrow stem cells, induced 
pluripotent stem cells, and neural stem cells. Grafting 
can be used by utilizing robots to calculate specific 
doses and tissue fixation agents in combination with 
neuronal differentiation-oriented proteins. 
In conclusion, all treated patients with motor 
and sensory deficits have shown improvement. 
Neurological muscle recovery and neurogenic bladder 
contraction improved significantly. The recovery rate 
was not high, although most of the treated patients 
had an improved quality of life and reported high 
satisfaction with the results of the treatment. 
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